In combination therapy, the therapeutic anti-PD-L1 mAb (10 F.9G2) releases PD-1/PD-L1 inhibition on T cells; CTL killing and antibody-mediated opsonization promote tumor-cell apoptosis and release of PD-L1 antigen, which is captured by APCs, reinforcing a positive feedback loop of antigen uptake, presentation, and effector activation. The gene discussed is CD274; the disease is neoplasm.